In the past year, we have made several new transgenic mice lines. We recently made the first apoC-II KO mice, using zinc finger technology. Similar to our patients with apoC-II deficiency, these mice in both the heterozygous and homozygous state had hypertriglyceridemia. We developed these mice to investigate the effect of an apoC-II mimetic peptide on triglyceride lipolysis and as a potential new therapy for patients with apoC-II deficiency. We also produced SR-BI transgenic mice and demonstrated in paper published last year in JLR that SR-BI serves as a receptor for the pro-atherogenic lipoprotein Lp(a). We also completed and published a study demonstrating that the selective endothelial expression of ABCA1, a key cholesterol efflux transporter, is anti-atherogenic. These new mouse lines will be invaluable in understanding the pathogenesis of atherosclerosis and will help guide us in developing new therapeutic strategies for the treatment of atherosclerosis.
Showing the most recent 10 out of 46 publications